Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.
2.

Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.

Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001.

PMID:
21190834
3.
4.

Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view.

van Hest RM, Mathot RA, Vulto AG, Ijzermans JN, van Gelder T.

Ther Drug Monit. 2006 Feb;28(1):31-4. Review.

PMID:
16418690
5.

Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation.

Filler G.

Pediatr Transplant. 2006 Sep;10(6):707-11. Review.

PMID:
16911495
6.

Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?

Staatz CE, Tett SE.

Clin Pharmacokinet. 2011 Dec 1;50(12):759-72. doi: 10.2165/11596380-000000000-00000. Review.

PMID:
22087863
7.

Therapeutic monitoring of mycophenolate in transplantation: is it justified?

Barraclough KA, Staatz CE, Isbel NM, Johnson DW.

Curr Drug Metab. 2009 Feb;10(2):179-87. Review.

PMID:
19275552
8.

Therapeutic drug monitoring of mycophenolate mofetil in transplantation.

van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD.

Ther Drug Monit. 2006 Apr;28(2):145-54. Review.

PMID:
16628123
9.

How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Abd Rahman AN, Tett SE, Staatz CE.

Clin Pharmacokinet. 2014 Mar;53(3):227-45. doi: 10.1007/s40262-013-0124-z. Review.

PMID:
24327238
10.

[Therapeutic drug monitoring of mycophenolate mofetil, sirolimus and cyclosporine at C2].

Royer B, Davani S, BĂ©rard M, Kantelip JP, Muret P.

Ann Biol Clin (Paris). 2003 May-Jun;61(3):251-8. Review. French.

11.

Utility of monitoring mycophenolic acid in solid organ transplant patients.

Oremus M, Zeidler J, Ensom MH, Matsuda-Abedini M, Balion C, Booker L, Archer C, Raina P.

Evid Rep Technol Assess (Full Rep). 2008 Feb;(164):1-131. Review.

12.

Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review.

Bruchet NK, Ensom MH.

Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1079-97. doi: 10.1517/17425250903114182. Review.

PMID:
19689217
13.

The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease.

Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA.

Clin Pharmacokinet. 2011 Jan;50(1):1-24. doi: 10.2165/11536640-000000000-00000. Review.

PMID:
21142265
Items per page

Supplemental Content

Support Center